6/4
08:40 am
howl
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $12.00 price target on the stock.
High
Report
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $12.00 price target on the stock.
6/3
11:04 pm
howl
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $9.00 price target on the stock.
High
Report
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $9.00 price target on the stock.
6/3
11:07 am
howl
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Medium
Report
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
6/1
09:08 am
howl
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors [Yahoo! Finance]
High
Report
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors [Yahoo! Finance]
6/1
09:00 am
howl
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
High
Report
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
5/30
08:54 am
howl
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference [Yahoo! Finance]
Medium
Report
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference [Yahoo! Finance]
5/30
08:00 am
howl
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
Medium
Report
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
5/24
08:04 am
howl
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Low
Report
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
5/23
05:00 pm
howl
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
Low
Report
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
5/6
05:07 pm
howl
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $9.00 price target on the stock.
Medium
Report
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $9.00 price target on the stock.
5/6
11:55 am
howl
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $12.00 price target on the stock.
Low
Report
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $12.00 price target on the stock.
5/6
08:06 am
howl
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Low
Report
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
5/3
07:11 am
howl
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
5/3
07:00 am
howl
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Low
Report
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
4/24
10:15 am
howl
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]
Low
Report
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]
4/24
10:05 am
howl
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Medium
Report
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
4/23
08:12 am
howl
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting [Yahoo! Finance]
Medium
Report
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting [Yahoo! Finance]
4/23
08:00 am
howl
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
Medium
Report
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
4/15
01:57 pm
howl
All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy [Yahoo! Finance]
Medium
Report
All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy [Yahoo! Finance]
4/5
04:38 pm
howl
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting [Yahoo! Finance]
High
Report
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting [Yahoo! Finance]
4/5
04:30 pm
howl
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
Medium
Report
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
4/4
04:45 pm
howl
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting [Yahoo! Finance]
Low
Report
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting [Yahoo! Finance]
4/4
04:30 pm
howl
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
Low
Report
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
4/3
08:08 am
howl
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) is now covered by analysts at JMP Securities. They set a "market outperform" rating and a $12.00 price target on the stock.
Medium
Report
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) is now covered by analysts at JMP Securities. They set a "market outperform" rating and a $12.00 price target on the stock.